Current status and future directions of cancer immunotherapy
Open Access
- 1 January 2018
- journal article
- review article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 9 (10), 1773-1781
- https://doi.org/10.7150/jca.24577
Abstract
In the past decades, our knowledge about the relationship between cancer and the immune system has increased considerably. Recent years' success of cancer immunotherapy including monoclonal antibodies (mAbs), cancer vaccines, adoptive cancer therapy and the immune checkpoint therapy has revolutionized traditional cancer treatment. However, challenges still exist in this field. Personalized combination therapies via new techniques will be the next promising strategies for the future cancer treatment direction.Keywords
This publication has 126 references indexed in Scilit:
- In vivo imaging of therapy-induced anti-cancer immune responses in humansCellular and Molecular Life Sciences, 2012
- Bioinformatics for cancer immunology and immunotherapyCancer Immunology, Immunotherapy, 2012
- Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigensJournal of Translational Medicine, 2012
- Cancer and Innate Immune System InteractionsJournal of Immunotherapy, 2012
- Expression of tumour-specific antigens underlies cancer immunoeditingNature, 2012
- Treating cancer with genetically engineered T cellsTrends in Biotechnology, 2011
- Enhanced Stimulation of Anti-Ovarian Cancer CD8+ T Cells by Dendritic Cells Loaded with Nanoparticle Encapsulated Tumor AntigenAmerican Journal of Reproductive Immunology, 2011
- Enhancement of humoral and cellular immunity with an anti-glucocorticoid-induced tumour necrosis factor receptor monoclonal antibodyImmunology, 2010
- Immunotherapy of cancerEuropean Journal of Pharmacology, 2009
- Cytokines in cancer pathogenesis and cancer therapyNature Reviews Cancer, 2004